Intravenous anidulafungin followed optionally by oral voriconazole for the treatment of candidemia in Asian patients: results from an open-label Phase III trial

Table 3 Clinical, microbiological, and global responses at the end of all treatment

Parameter	MITT population	PP population
Clinical response, % [n/N]
Success (95% CI)	76.2 (60.5–87.9) [32/42]	82.4 (65.5–93.2) [28/34]
Cure	64.3 [27/42]	67.6 [23/34]
Improvement	11.9 [5/42]	14.7 [5/34]
Failure^a	4.8 [2/42]	5.9 [2/34]
Indeterminate	14.3 [6/42]	5.9 [2/34]
Not assessed	4.8 [2/42]	5.9 [2/34]
Microbiological response, % [n/N]
Success (95% CI)	81.0 (65.9–91.4) [34/42]	82.4 (65.5–93.2) [28/34]
Eradication	73.8 [31/42]	73.5 [25/34]
Presumed eradication	7.1 [3/42]	8.8 [3/34]
Failure	2.4 [1/42]	2.9 [1/34]
Not assessed	16.7 [7/42]	14.7 [5/34]
Global response, % [n/N]
Success (95% CI)	73.8 (58.0–86.1) [31/42]	79.4 (62.1–91.3) [27/34]
Failure	11.9 [5/42]	8.8 [3/34]
Not assessed	14.3 [6/42]	11.8 [4/34]

Abbreviations used: CI, confidence interval; MITT, modified intent-to-treat; PP, per protocol.

ISSN: 1471-2334